YOLFTbeta
Tyra Biosciences Inc

Tyra Biosciences Inc

TYRA · NASDAQ · Healthcare / Biotechnology

20.03USD+0.26 (+1.32%)

Price History

Full chart

Market Stats

Previous Close19.77
Open19.99
Day Range19.27 – 20.12
52-Week Range12.98 – 40.65
Volume375.09K
Market Cap1.50B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.39
Dividend Yield0.00%
Beta0.73
50-Day Avg27.07
200-Day Avg30.54

About

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Todd Harris Ph.D.
  • Employees87
  • Headquarters2656 State Street, Carlsbad, CA, United States, 92008, USA
  • Websitehttps://tyra.bio

Leadership

  • Dr. Todd Harris Ph.D.Co-Founder, CEO, President & Director · b. 1979
  • Mr. Bhavesh Ashar M.B.A.Chief Operating Officer · b. 1969
  • Dr. Douglas Warner M.D.Chief Medical Officer · b. 1972
  • Mr. Daniel BensenCo-Founder & Chief Discovery Officer · b. 1975
  • Mr. Alan Fuhrman CPAChief Financial Officer · b. 1957
  • Ms. Julia RuebVP of Finance & Principal Accounting Officer · b. 1986
  • Dr. Robert L. Hudkins Ph.D.Chief Technology Officer · b. 1955
  • Dr. Ronald V. Swanson Ph.D.Chief Scientific Officer · b. 1963
  • Mr. Ali D. Fawaz J.D.General Counsel & Secretary
  • Ms. Sarah HonigSenior VP of Corporate Development & Strategy

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Cost of Revenue8.00K47.00K140.00K296.00K353.00K519.00K546.00K
Gross Profit-8.00K-47.00K-140.00K-296.00K-353.00K-519.00K-546.00K
Operating Expense3.11M9.25M26.15M58.63M79.59M103.66M132.22M
Operating Income-3.12M-9.30M-26.29M-58.93M-79.94M-104.18M-132.76M
EBITDA-3.11M-9.25M-26.15M-58.63M-68.78M-85.96M-119.40M
Net Income-4.06M-9.31M-26.14M-51.72M-69.13M-86.48M-119.95M
R&D1.79M7.20M20.64M43.01M62.52M80.08M102.93M
Interest Expense1.00K1.00K140.00K296.00K---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets528.00K16.01M306.70M266.18M225.86M363.56M282.61M
Total Liabilities5.27M29.65M4.96M8.35M21.59M20.41M23.43M
Total Equity-4.74M-13.64M301.74M257.83M204.26M343.15M259.18M
Cash108.00K15.22M302.18M251.21M58.01M91.97M77.39M
Total Debt253.00K142.00K1.18M2.62M6.50M6.22M5.81M
Net Debt145.00K-15.08M-301.00M-248.59M-51.51M-85.74M-71.58M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.62M-7.76M-23.75M-50.28M-50.14M-69.77M-95.14M
Investing Cash Flow-20.00K-312.00K-645.00K-559.00K-144.60M-98.40M72.46M
Financing Cash Flow157.00K23.43M311.35M632.00K1.54M202.14M8.10M
Capital Expenditure20.00K312.00K661.00K559.00K770.00K664.00K141.00K
Free Cash Flow-2.64M-8.07M-24.41M-50.84M-50.91M-70.44M-95.28M
FCF to OCF100.76%104.02%102.78%101.11%101.54%100.95%100.15%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021May 28, 2021Sep 15, 2021Nov 3, 2021Mar 3, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 22, 2023May 4, 2023Aug 10, 2023Nov 7, 2023Mar 19, 2024May 9, 2024Aug 7, 2024Nov 7, 2024Mar 27, 2025May 8, 2025Aug 14, 2025Nov 5, 2025Mar 2, 2026Apr 30, 2026Aug 4, 2026Nov 4, 2026
EPS Estimate0.000.000.000.000.000.000.00-0.60-0.21-0.20-0.30-0.39-0.36-0.37-0.34-0.35-0.48-0.46-0.39-0.39-0.48-0.48-0.51-0.50-0.53-0.58-0.67-0.66
EPS Actual-1.07-1.27-1.80-1.80-2.09-0.04-0.24-0.72-0.24-0.36-0.36-0.30-0.31-0.28-0.31-0.49-0.53-0.35-0.32-0.41-0.43-0.47-0.47-0.50-0.57-0.64-0.69-
Surprise--------20.00%-14.29%-80.00%-20.00%23.08%13.89%24.32%8.82%-40.00%-10.42%23.91%17.95%-5.13%10.42%2.08%7.84%0.00%-7.55%-10.34%-2.99%-
Timing------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.50B
Enterprise Value1.25B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book4.52
EPS-2.39
Book Value5.93
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-159.92M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-45.31%
Return on Assets-28.46%
Shares Outstanding68.76M
Shares Float34.65M
Beta0.73
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 47.45
  • Strong Buy
    6
  • Buy
    2

Ownership Breakdown

Institutions
108.40%
Insiders
2.49%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    12.20M20.44%
  • FMR Inc
    7.75M12.98%
  • HHG PLC
    3.89M6.52%
  • Alta Partners Management Company, L.P.
    3.82M6.41%
  • Farallon Capital Management, L.L.C.
    3.58M6.00%
  • Nextech Invest, Ltd.
    3.55M5.95%
  • TCG Crossover Management, LLC
    3.25M5.44%
  • COMMODORE CAPITAL LP
    2.48M4.15%
  • BlackRock Inc
    2.22M3.72%
  • Bvf Inc
    1.98M3.31%
  • Paradigm Biocapital Advisors LP
    1.83M3.06%
  • State Street Corp
    1.22M2.04%
  • Vanguard Capital Management, LLC
    1.13M1.89%
  • 5AM Venture Management, LLC
    1.03M1.72%
  • T. Rowe Price Associates, Inc.
    986.06K1.65%
  • Barclays PLC
    833.40K1.40%

Top Fund Holders

  • Fidelity OTC
    3.30M5.52%
  • State Street® SPDR® S&P® Biotech ETF
    1.47M2.46%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.14M1.90%
  • iShares Russell 2000 ETF
    938.02K1.57%